Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis
Top Cited Papers
Open Access
- 9 September 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Medical Genetics
- Vol. 12 (1), 118
- https://doi.org/10.1186/1471-2350-12-118
Abstract
Despite some studies suggesting a possible association between human leukocyte antigen, HLA-B*5801 and allopurinol induced Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), the evidence of association and its magnitude remain inconclusive. This study aims to systematically review and meta-analyze the association between HLA-B*5801 allele and allopurinol-induced SJS/TEN. A comprehensive search was performed in databases including MEDLINE, Pre-MEDLINE, Cochrane Library, EMBASE, International Pharmaceutical Abstracts (IPA), CINAHL, PsychInfo, the WHO International, Clinical Trial Registry, and ClinicalTrial.gov from their inceptions to June 2011. Only studies investigating association between HLA-B*5801 with allopurinol-induced SJS/TEN were included. All studies were extracted by two independent authors. The primary analysis was the carrier frequency of HLA-B*5801 comparison between allopurinol-induced SJS/TEN cases and each comparative group. The pooled odds ratios were calculated using a random effect model. A total of 4 studies with 55 SJS/TEN cases and 678 matched-controls (allopurinol-tolerant control) was identified, while 5 studies with 69 SJS/TEN cases and 3378 population-controls (general population) were found. SJS/TEN cases were found to be significantly associated with HLA-B*5801 allele in both groups of studies with matched-control (OR 96.60, 95%CI 24.49-381.00, p < 0.001) and population-control (OR 79.28, 95%CI 41.51-151.35, p < 0.001). Subgroup analysis for Asian and Non-Asian population yielded similar findings. We found a strong and significant association between HLA-B*5801 and allopurinol-induced SJS/TEN. Therefore, HLA-B*5801 allele screening may be considered in patients who will be treated with allopurinol.Keywords
This publication has 47 references indexed in Scilit:
- Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in KoreansPharmacogenetics and Genomics, 2011
- Causal assessment of smoking and tooth loss: A systematic review of observational studiesBMC Public Health, 2011
- Drug hypersensitivity: Pharmacogenetics and clinical syndromesJournal of Allergy and Clinical Immunology, 2011
- Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysisBMC Pregnancy and Childbirth, 2010
- The effect of alcohol advertising, marketing and portrayal on drinking behaviour in young people: systematic review of prospective cohort studiesBMC Public Health, 2009
- Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and IsraelJournal of the American Academy of Dermatology, 2008
- Systematic reviews of adverse effects: framework for a structured approachBMC Medical Research Methodology, 2007
- Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactionsPharmacogenetics and Genomics, 2006
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986